Drusen on a routine eye exam: what it means and what to do next

It is a strange kind of news. You went in for a routine eye exam expecting a new glasses prescription, and instead your eye doctor mentioned, almost in passing, that you have "some drusen." Maybe they said it was nothing to worry about; maybe they said they wanted to keep an eye on it. Either way you went home, searched the word, and hit a wall of frightening pages about macular degeneration and blindness. The reality is more measured than the search results, and the details matter.

The short version: drusen are yellowish deposits that build up under the retina. A few small ones are a normal part of aging. What changes the picture is size and number — medium drusen indicate early age-related macular degeneration (AMD), and large drusen indicate intermediate AMD with a higher chance of progression. Most people never progress to vision-threatening disease, and the sensible response is monitoring, not panic. Here is what the categories mean and what to actually do.

What drusen are

Underneath the light-sensing retina sits a busy support layer — the retinal pigment epithelium — and beneath that, a thin boundary called Bruch's membrane. Over years, metabolic waste products that the retina would normally clear can accumulate in this zone, forming small deposits. Seen through the pupil on an eye exam, they look like discrete pale-yellow spots. Those are drusen (singular: druse, from the German for "geode").

Not all drusen are alike, and the differences are the whole story:

• Hard drusen are small, well-defined, and extremely common with age. A scattering of them, on their own, is considered a normal aging change.
• Soft drusen are larger, with fuzzier borders, and can merge together. These are the ones associated with age-related macular degeneration.
• Reticular pseudodrusen (subretinal drusenoid deposits) sit in a different layer and are associated with a higher risk of progression; your eye doctor may mention them separately if imaging shows them.

A druse is not a blockage or a growth. It is a marker — a sign of how the aging retina and its support tissue are coping. The clinically useful question is not "do I have drusen" (many older adults do) but "what size, how many, and are there pigment changes."

Size is the risk dial

The field settled on a shared way to grade this, the Beckman clinical classification, precisely so that "you have drusen" could be turned into a risk statement (Ferris et al., 2013). It is based on what an eye doctor can see on examination or a color photograph — drusen size and whether there are pigment abnormalities in the macula — and it sorts eyes into stages:

• Small drusen (under about 63 microns, roughly the width of a fine human hair): considered normal aging changes, with no clinically meaningful increase in the risk of late AMD.
• Medium drusen (about 63 to under 125 microns), without pigment changes: classified as early AMD.
• Large drusen (125 microns or larger), or medium drusen with associated pigment changes: classified as intermediate AMD, which carries a higher risk of progressing to late, vision-threatening AMD.
• Late AMD is defined by either geographic atrophy (loss of retinal tissue) or neovascular ("wet") disease — the stages that actually threaten central vision.

The reason your eye doctor cares about the micron threshold is that it maps to risk. Large drusen and pigment changes are the features that most raise the odds of eventual progression. But it is worth holding both halves of that sentence: risk rises with size, and most people with drusen — including many with intermediate AMD — still never reach the late, sight-threatening stages. Monitoring exists to catch the minority who do, early.

Why your vision can still be "perfect"

Here is the part that surprises people: you can have drusen, even intermediate AMD, and read the 20/20 line without difficulty. Standard visual acuity — the eye chart — tests fine, high-contrast detail at the very center, and that capability is often preserved until AMD is fairly advanced. This is exactly why drusen are usually an incidental finding on a routine exam rather than something you noticed.

But "the eye chart is normal" is not the same as "visual function is untouched." Several studies have found that contrast sensitivity is reduced in eyes with drusen and normal visual acuity. Midena and colleagues reported that contrast sensitivity loss was a consistent finding in eyes with drusen despite normal acuity, most pronounced in the middle-to-high spatial-frequency range (Midena et al., 1997). In plainer terms: the fine-and-faint end of vision — the newspaper texture, the low-contrast edge — can soften before the high-contrast eye chart budges. Reduced foveal contrast sensitivity, poorer low-luminance acuity, and delayed dark adaptation are all documented in early AMD.

This is why contrast sensitivity is interesting here, and also why we are careful about it. It is a functional signal that can shift early. It is not a way to diagnose or stage AMD — that is what the dilated exam and retinal imaging are for. Our deeper pieces on AMD and contrast as an early signal and the 20-minute dark-adaptation curve cover the functional-change story in more detail.

Note: a contrast sensitivity test is a screening signal of overall visual function. It does not diagnose or stage AMD, cannot see drusen, and does not replace the dilated exam and retinal imaging that classify your risk.

What to actually do next

Drusen call for a short, practical checklist — not a crisis.

1. Find out your category. Ask your eye doctor, in plain terms, whether your drusen are small, medium, or large, whether there are pigment changes, and whether this is being called normal aging, early AMD, or intermediate AMD. That single answer determines everything else. If you did not get it at the visit, it is a fair thing to phone back about. Our guide to reading your eye exam report can help you decode what was written down.

2. Keep the monitoring cadence. Your eye doctor will set a follow-up interval based on your category — more frequent for intermediate AMD, less for a few small drusen. The exams may include optical coherence tomography (OCT), which images the retinal layers and can pick up early fluid, and fundus photography to track drusen over time. These monitoring visits are the point; keep them.

3. Ask about supplements if you have intermediate AMD. The Age-Related Eye Disease Study (AREDS), a large randomized trial, found that a specific antioxidant-and-mineral formula reduced the risk of progression to advanced AMD in people who already had intermediate or advanced disease in at least one eye (AREDS Research Group, 2001); the later AREDS2 study refined the formula. These supplements are for people who are already at that stage — they are not a general preventive for everyone with a few small drusen, and they are a conversation to have with your eye doctor, who can weigh your specifics.

4. Learn a home-monitoring method. An Amsler grid — a simple grid of straight lines with a central dot — lets you check each eye for new distortion at home between visits. Its sensitivity is limited (more on that in our comparison of home vision tests), but it is quick and free, and the habit of checking one eye at a time matters.

5. Know the urgent signal. The event that changes management is a conversion to neovascular ("wet") AMD, where new, leaky vessels grow under the retina. Its warning signs are sudden: straight lines (door frames, window edges) appearing bent or wavy, a new blurry or dark spot in your central vision, or a rapid drop in central vision in one eye. That is not a "wait for the next appointment" situation — it warrants prompt evaluation, because the wet form is treatable and earlier treatment protects more vision.

6. The general risk factors still apply. Not smoking, managing blood pressure, and a diet rich in leafy greens and fish are associated with lower AMD risk across the population. None of these are guarantees, and none replace monitoring, but they are worth doing anyway.

The honest summary

Drusen are a spectrum, and where you sit on it is a specific, knowable fact — small, medium, or large; with or without pigment changes. A few small drusen are ordinary aging. Larger drusen mean a higher risk that is worth watching, not a sentence. Your central acuity can be fine while contrast and low-light vision have softened, which is why functional tracking is interesting and why monitoring matters. Get your category, keep your appointments, ask about supplements if you qualify, and treat sudden distortion as urgent.

If you want a functional baseline to revisit between exams, you can take a free contrast sensitivity test. Retake it on the same device under similar conditions, and bring any sustained change — along with any new distortion — to your eye doctor. It is a companion to monitoring, not a substitute for the exam that classifies your drusen.

References

• Ferris, F. L., Wilkinson, C. P., Bird, A., Chakravarthy, U., Chew, E., Csaky, K., & Sadda, S. R. (2013). Clinical classification of age-related macular degeneration (Beckman Initiative for Macular Research Classification Committee). Ophthalmology, 120(4), 844–851. Defines the drusen-size categories (small under 63 µm, medium 63 to under 125 µm, large 125 µm or larger) and the early/intermediate/late AMD staging used here.
• Midena, E., Degli Angeli, C., Blarzino, M. C., Valenti, M., & Segato, T. (1997). Macular function impairment in eyes with early age-related macular degeneration. Investigative Ophthalmology & Visual Science, 38(2), 469–477. Found reduced contrast sensitivity and other functional deficits in eyes with drusen despite normal visual acuity.
• Age-Related Eye Disease Study Research Group. (2001). A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Archives of Ophthalmology, 119(10), 1417–1436. The trial establishing that a specific supplement formula reduces progression risk in people with intermediate or advanced AMD.